Browse the evidence

For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.

If you have Class III obesity (BMI >39.9), surgery is the most effective treatment available. Medications like semaglutide are significantly less effective than surgery for this group. If you are not a candidate for surgery or refuse it, medication is still an option, but you should expect less weight loss compared to surgical outcomes.

Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are more effective than adjustable gastric banding (AGB) for weight loss and quality of life in severe obesity, with RYGB providing superior weight loss compared to SG.

If you have severe obesity and are considering surgery, Roux-en-Y gastric bypass offers the best chance for significant, lasting weight loss and improved quality of life. Sleeve gastrectomy is a good alternative if bypass is not possible, but expect less weight loss. Adjustable gastric banding is not recommended as it is significantly less effective. Discuss these options with a specialist bariatric team to determine the best fit for your health profile.

Consumption of sugar-sweetened beverages (SSBs) is causally associated with a significant global burden of incident type 2 diabetes (T2D) and cardiovascular disease (CVD), mediated by both direct metabolic effects and adiposity.

Reduce or eliminate sugar-sweetened beverages to significantly lower your risk of developing type 2 diabetes and cardiovascular disease. The risk is not just from weight gain but from how sugar is metabolized directly. This is especially critical if you are young, male, or live in urban areas in high-burden regions like Latin America or Sub-Saharan Africa.

Protein supplementation augments strength and hypertrophy.

If you are doing resistance training, protein supplementation can help you build more strength and muscle.

Creatine supplementation augments strength.

Creatine supplementation is an effective way to increase strength when combined with resistance training.

Adherence to the DASH dietary pattern reduces systolic blood pressure by 1–13 mm Hg and diastolic blood pressure by 1–10 mm Hg, with effects amplified when combined with weight loss or sodium restriction.

Adopt the DASH diet by prioritizing fruits, vegetables, low-fat dairy, and whole grains while limiting saturated fats and sugars. This approach is clinically proven to lower blood pressure significantly, often matching the effectiveness of standard blood pressure medications, especially if you also manage your weight and sodium intake.

Creatine supplementation combined with resistance training significantly increases fat-free mass (FFM) and body mass in both novice and experienced lifters, with experienced lifters gaining approximately 0.6 kg more FFM than novices, though this difference is not statistically significant.

If you are lifting weights, adding creatine will help you gain more muscle and body weight than training alone. This benefit applies whether you are just starting out or have been training for years. While experienced lifters might gain slightly more muscle than beginners, the difference isn't statistically significant, meaning creatine is a valuable tool for everyone.

Short sleep duration (less than 5 hours per night) is significantly associated with an increased risk of obesity, with an odds ratio of 1.89 in children and 1.55 in adults.

Aim for 7-8 hours of sleep per night. Sleeping less than 5 hours significantly increases your risk of obesity. Prioritize sleep as a key component of your metabolic health strategy.

Unhealthy lifestyle factors (current smoking, low physical activity, and low dietary adherence) increase the risk of myocardial infarction and coronary heart disease, with elevated remnant cholesterol explaining 12-21% of this excess risk.

Your lifestyle choices directly impact a specific type of fat in your blood called remnant cholesterol, which contributes to heart disease risk. Quitting smoking, increasing physical activity, and adhering to dietary guidelines can lower these levels, thereby reducing your risk of heart attack and coronary heart disease. This reduction in risk is partly mediated by the improvement in your remnant cholesterol levels.

Obesity is a chronic disease of dysregulated energy balance involving neuroendocrine factors, requiring lifelong, multimodal management (lifestyle, pharmacotherapy, surgery) tailored to individual patient characteristics and evolving goals.

Treat obesity as a chronic disease requiring long-term management. Work with your healthcare provider to create a personalized plan involving lifestyle changes, medications, or surgery based on your specific health needs and goals. Regular follow-up is essential to adjust treatment as your needs change.

High-intensity interval exercise (HIIE) induces time-dependent transcriptomic changes in skeletal muscle that persist for at least 48 hours, with the magnitude of expression for 60% of genes being influenced by cardiorespiratory fitness.

To maximize molecular adaptations, ensure your exercise intensity is relative to your current fitness level (e.g., using lactate threshold or max work rate) rather than a fixed percentage. Recognize that the body's molecular response to exercise continues for up to 48 hours, with significant changes occurring well after the workout ends. This applies to both men and women when fitness levels are comparable.

Individuals with Type 2 Diabetes (T2D) exhibit significantly reduced cardiorespiratory fitness (CRF), measured as peak oxygen uptake (VO2peak), compared to healthy controls, with reductions averaging 13.9% for absolute VO2peak and 17.4% for relative VO2peak.

If you have Type 2 Diabetes, expect your maximum oxygen uptake to be lower than a healthy peer's, even if you feel fine. This is a physiological marker of the disease, not a lack of effort. Start exercise interventions at a lower intensity to manage early fatigue, and focus on consistency rather than high intensity initially, as improving this baseline fitness is critical for long-term health outcomes.

Higher BMI, particularly severe obesity (Class 2 and 3), is robustly associated with increased risk of heart failure and atrial fibrillation, independent of traditional risk factors.

Maintaining a healthy weight is critical for preventing heart failure and irregular heartbeats. Severe obesity significantly increases these risks, even if your blood pressure and cholesterol are managed. Weight management should be treated as a primary medical intervention to protect heart health.

Higher BMI categories, particularly Class III obesity (BMI ≥40 kg/m2), are strongly associated with worse self-reported overall health, quality of life, severe pain, fatigue, and limited physical activity, as well as an increased risk of developing chronic pain syndrome, chronic fatigue syndrome, fibromyalgia, and insomnia.

If you have obesity, do not ignore persistent pain, fatigue, or sleep issues. These are not just 'side effects' of weight but significant health risks linked to conditions like fibromyalgia and chronic fatigue. Seek medical evaluation for these symptoms, as treating them can improve your quality of life and functional ability, independent of weight loss goals.

Obesity is a chronic, relapsing disease driven by disruptions in homeostatic, hedonic, and cognitive systems, rather than solely a lifestyle outcome, and requires multidisciplinary management including pharmacotherapy and surgery.

Treat obesity as a chronic disease, not a lifestyle failure. For eligible patients, GLP-1 agonists like semaglutide (2.4 mg weekly) combined with lifestyle changes produce significant weight loss (approx. 15%). Manage GI side effects with slow titration. Consider surgery for BMI ≥35.

Obesity is a primary driver of Heart Failure with Preserved Ejection Fraction (HFpEF) through cardiometabolic mechanisms including systemic inflammation, lipotoxicity, and metabolic remodeling, rather than being merely a comorbidity.

If you have HFpEF and obesity, your body's metabolism and inflammation are likely driving your heart condition. This is not just about 'being overweight' but involves complex biological changes like fat toxicity and inflammation. Managing obesity through weight loss interventions (like GLP-1 agonists or lifestyle changes) can target these root causes and improve heart health.

Imaging-based body composition assessment (DXA, CT, or MRI) is required to demonstrate that weight loss from anti-obesity drugs is attributable to fat mass reduction rather than lean mass loss, as mandated by updated US FDA and Korean MFDS guidelines.

If you are taking anti-obesity medication, ask your provider about body composition analysis (DXA or CT) rather than relying solely on weight. This ensures your weight loss is coming from fat stores and not muscle tissue, which is critical for long-term metabolic health and is now a regulatory standard for drug approval.

DXA is the preferred imaging modality for anti-obesity drug trials due to its balance of low radiation, cost-effectiveness, and accessibility, although CT and MRI offer superior precision for visceral fat and muscle quality assessment.

For most obesity drug trials, DXA is the standard imaging tool because it is cheap, safe, and widely available. However, if detailed analysis of visceral fat or muscle quality (myosteatosis) is needed, CT or MRI may be used despite higher costs.

Current hypertension guidelines do not yet recommend incretin-based therapies as first-line treatment because no large-scale trial has used blood pressure reduction as its primary endpoint, despite robust secondary data showing efficacy.

You cannot currently get GLP-1 medications prescribed specifically for high blood pressure as a first-line treatment under standard insurance guidelines. They are primarily approved for diabetes and weight loss. However, if you have both hypertension and obesity/diabetes, your doctor may prescribe them for those conditions, which will incidentally lower your blood pressure significantly.

BMI is an insufficient diagnostic tool for obesity because it fails to differentiate between fat mass and lean body mass, leading to misclassification.

Do not rely solely on BMI to determine your health status. It fails to distinguish between muscle and fat. Ask your doctor for more precise assessments like waist circumference or body composition analysis to get a true picture of your metabolic risk.

Current food environment policies in Vietnam are insufficient, with 74% of assessed indicators scoring low or very low, particularly in food composition standards, marketing, and labeling.

Policymakers must move beyond food safety regulations to address nutritional quality. This requires implementing mandatory food composition standards (e.g., sugar/salt/trans-fat limits), restricting marketing of unhealthy foods (especially to children), and enforcing front-of-package labeling.

Bariatric surgery remains the most effective long-term treatment for severe obesity, offering superior durability and comorbidity remission compared to pharmacotherapy.

For severe obesity, surgery is still the most durable and effective option for long-term health improvement. It offers better comorbidity remission than drugs alone. Consider it if your BMI is very high or you have serious health issues.

Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG) are highly effective surgical interventions for severe obesity, with RYGB showing slightly greater long-term weight loss.

Surgical options like RYGB and SG are highly effective for severe obesity, leading to 47-55% excess weight loss over seven years. RYGB tends to result in slightly greater weight loss than SG, but both improve quality of life. These are major surgeries requiring careful patient selection and postoperative management.

There is a significant disconnect between mechanistic research (e.g., mTOR signaling) and applied intervention studies, leading to a lack of systematic translation of basic science into concrete intervention strategies.

Current research often fails to bridge the gap between molecular science and practical advice. For now, focus on the proven basics: consistent resistance training and adequate protein intake, rather than trying to optimize based on complex molecular mechanisms that haven't been fully translated into practical protocols.